ParkinsonCanadaV1, Main, Exploration, bibRecord, 000619

ON-OFF Effects of Dopaminergic Therapy on Psychiatric Symptoms in Parkinson's Disease.

Identifieur interne : 000619 ( Main/Exploration ); précédent : 000618; suivant : 000620

ON-OFF Effects of Dopaminergic Therapy on Psychiatric Symptoms in Parkinson's Disease.

Auteurs : Hooman Ganjavi [Canada] ; Penny A. Macdonald

Source :

The Journal of neuropsychiatry and clinical neurosciences [ 1545-7222 ] ; 2015.

RBID : pubmed:25923857

English descriptors

KwdEn :
- Aged, Analysis of Variance, Antipsychotic Agents (therapeutic use), Case-Control Studies, Dopamine Agents (therapeutic use), Female, Humans, Male, Middle Aged, Parkinson Disease (complications), Psychiatric Status Rating Scales, Psychotic Disorders (drug therapy), Psychotic Disorders (etiology).
MESH :
- chemical , therapeutic use : Antipsychotic Agents, Dopamine Agents.
- complications : Parkinson Disease.
- drug therapy : Psychotic Disorders.
- etiology : Psychotic Disorders.
- Aged, Analysis of Variance, Case-Control Studies, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales.

Abstract

Psychiatric manifestations of Parkinson's disease (PD) are a cause of significant disability and the impact of dopaminergic medications is unclear. Using standardized rating scales, the authors tested the hypothesis that anxiety, depression, and apathy vary in the ON versus OFF states in PD in 33 PD patients and 29 healthy age- and education-matched controls. PD patients had significantly higher anxiety, depression, and apathy scores than control participants, regardless of ON-OFF state. Anxiety scores were higher in PD patients on relative to off dopaminergic medication. The ON-OFF difference in anxiety related to degree of improvement in motor function but not illness duration.

DOI: 10.1176/appi.neuropsych.14030055
PubMed: 25923857

Affiliations:

Canada

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">ON-OFF Effects of Dopaminergic Therapy on Psychiatric Symptoms in Parkinson's Disease.</title>
<author><name sortKey="Ganjavi, Hooman" sort="Ganjavi, Hooman" uniqKey="Ganjavi H" first="Hooman" last="Ganjavi">Hooman Ganjavi</name>
<affiliation wicri:level="1"><nlm:affiliation>From the Dept. of Psychiatry, University of Western Ontario, London, Ontario, Canada (HG); The Brain and Mind Institute, University of Western Ontario, London, Ontario, Canada (PAM); and Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario, Canada (PAM).</nlm:affiliation>
<country>Canada</country>
<wicri:regionArea>From the Dept. of Psychiatry, University of Western Ontario, London, Ontario, Canada (HG); The Brain and Mind Institute, University of Western Ontario, London, Ontario, Canada (PAM); and Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Macdonald, Penny A" sort="Macdonald, Penny A" uniqKey="Macdonald P" first="Penny A" last="Macdonald">Penny A. Macdonald</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25923857</idno>
<idno type="pmid">25923857</idno>
<idno type="doi">10.1176/appi.neuropsych.14030055</idno>
<idno type="wicri:Area/PubMed/Corpus">000601</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000601</idno>
<idno type="wicri:Area/PubMed/Curation">000601</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000601</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000601</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000601</idno>
<idno type="wicri:Area/Ncbi/Merge">001B51</idno>
<idno type="wicri:Area/Ncbi/Curation">001B51</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001B51</idno>
<idno type="wicri:Area/Main/Merge">000620</idno>
<idno type="wicri:Area/Main/Curation">000619</idno>
<idno type="wicri:Area/Main/Exploration">000619</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">ON-OFF Effects of Dopaminergic Therapy on Psychiatric Symptoms in Parkinson's Disease.</title>
<author><name sortKey="Ganjavi, Hooman" sort="Ganjavi, Hooman" uniqKey="Ganjavi H" first="Hooman" last="Ganjavi">Hooman Ganjavi</name>
<affiliation wicri:level="1"><nlm:affiliation>From the Dept. of Psychiatry, University of Western Ontario, London, Ontario, Canada (HG); The Brain and Mind Institute, University of Western Ontario, London, Ontario, Canada (PAM); and Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario, Canada (PAM).</nlm:affiliation>
<country>Canada</country>
<wicri:regionArea>From the Dept. of Psychiatry, University of Western Ontario, London, Ontario, Canada (HG); The Brain and Mind Institute, University of Western Ontario, London, Ontario, Canada (PAM); and Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Macdonald, Penny A" sort="Macdonald, Penny A" uniqKey="Macdonald P" first="Penny A" last="Macdonald">Penny A. Macdonald</name>
</author>
</analytic>
<series><title level="j">The Journal of neuropsychiatry and clinical neurosciences</title>
<idno type="eISSN">1545-7222</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Analysis of Variance</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Case-Control Studies</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (complications)</term>
<term>Psychiatric Status Rating Scales</term>
<term>Psychotic Disorders (drug therapy)</term>
<term>Psychotic Disorders (etiology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term>
<term>Dopamine Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Analysis of Variance</term>
<term>Case-Control Studies</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Psychiatric Status Rating Scales</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Psychiatric manifestations of Parkinson's disease (PD) are a cause of significant disability and the impact of dopaminergic medications is unclear. Using standardized rating scales, the authors tested the hypothesis that anxiety, depression, and apathy vary in the ON versus OFF states in PD in 33 PD patients and 29 healthy age- and education-matched controls. PD patients had significantly higher anxiety, depression, and apathy scores than control participants, regardless of ON-OFF state. Anxiety scores were higher in PD patients on relative to off dopaminergic medication. The ON-OFF difference in anxiety related to degree of improvement in motor function but not illness duration.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><noCountry><name sortKey="Macdonald, Penny A" sort="Macdonald, Penny A" uniqKey="Macdonald P" first="Penny A" last="Macdonald">Penny A. Macdonald</name>
</noCountry>
<country name="Canada"><noRegion><name sortKey="Ganjavi, Hooman" sort="Ganjavi, Hooman" uniqKey="Ganjavi H" first="Hooman" last="Ganjavi">Hooman Ganjavi</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000619 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000619 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:25923857
   |texte=   ON-OFF Effects of Dopaminergic Therapy on Psychiatric Symptoms in Parkinson's Disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:25923857" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

ON-OFF Effects of Dopaminergic Therapy on Psychiatric Symptoms in Parkinson's Disease.

ON-OFF Effects of Dopaminergic Therapy on Psychiatric Symptoms in Parkinson's Disease.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.